跳至主要内容
临床试验/NCT04869930
NCT04869930Unknown不适用

Establishing a Diagnostic and Therapeutic Index in Autism Spectrum Disorder (ASD) and Fragile X Syndrome

Nova Mentis Life Science Corp1 个研究点 分布在 1 个国家目标入组 300 人开始时间: 2021年11月1日最近更新:
适应症

试验速览

阶段
不适用
入组人数
300
试验地点
1
主要终点
microbial diversity profile

研究概览

简要总结

The purpose of this study is to accumulate and quantitatively analyze data on the microbiome, serotonin signaling and genetics, and inflammatory cytokines from patients with Autism Spectrum Disorder and Fragile X Syndrome. Computational analysis of multi-dimensional datasets will be used to establish a "Diagnostic and Therapeutic Index" - an objective set of tools that can help differentiate subtypes of Autism Spectrum Disorder and develop more accurate methods of diagnosis and response to treatment.

研究设计

研究类型
Observational
观察模型
Case Control
时间视角
Cross Sectional

入排标准

年龄范围
6 Months 至 21 Years(Child, Adult)
性别
All
接受健康志愿者

入选标准

  • Early childhood (pre-diagnosis) OR existing ASD diagnosis (Moderate to Severe)
  • Existing FXS diagnosis

排除标准

  • Hospitalization
  • Enrolled in another clinical study

结局指标

主要结局

microbial diversity profile

时间窗: 2 years

genetic analysis of microbial species in fecal samples

次要结局

  • differences in serotonin levels(2 years)
  • differential expression of serotonin-related signaling molecules(2 years)

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验

Establishing a Diagnostic and Therapeutic Index in... | 临床试验